Dr. Dunckley and his team will perform characterization of DYR compounds using in vitro and cell-based assays. He will also perform in vivo testing of select, optimized compounds in the 3XTg-AD mouse model and conduct behavioral and neuropathological experiments on treated and untreated cohorts.
|Effective start/end date||4/1/20 → 2/28/21|
- HHS: National Institutes of Health (NIH): $1,075,080.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.